retatrutide phase 3 FDA Approval Status 2026: Everything We Know So Far retatrutide phase 3 results The

They were also 50% less likely to die of a drug overdose or other SUD-related cause

Subjects and Measurements: This study was a pre-planned sub-study of the Combat-JUDO trial, set at the Pediatric clinic at Uppsala University Hospital, Sweden and Paracelsus Medical University, Austria

It also poses a significant risk of false-negative imaging results when assessing for colonic or genitourinary tumours

I thought, wow, this sounds really interesting, she says

However, the pivotal 36-week Phase 2 trial showed a larger range of mean loss, from 9.4% to 14.7%, across doses, confirming robust dose-dependent effects

The human results were real but modest